• Explore /
  • Poster
  • / Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

Abstract Poster

Authors

null

Yosuke Kito

Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

Yosuke Kito , Eisuke Inoue , Yusuke Akamaru , Masazumi Takahashi , Jin Matsuyama , Hiroshi Yabusaki , Akitaka Makiyama , Takahisa Suzuki , Masahiro Tsuda , Hisateru Yasui , Naoki Hirabayashi , Atsushi Takeno , Hisato Kawakami , Hiroyuki Okuda , Takashi Yoshioka , Junji Kawada , Yasuhiro Kodera , Wataru Ichikawa , Masashi Fujii , Yu Sunakawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

UMIN000030850

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4044)

DOI

10.1200/JCO.2021.39.15_suppl.4044

Abstract #

4044

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ryohei Kawabata

First Author: Kohei Shitara

First Author: Ian Chau

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.

Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.

First Author: Mai Utsumi